Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon?) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy

摘要

The human immunodeficiency virus type 1 fusion inhibitor T-20 (Enfuvirtide, Fuzeon®) has recently been introduced into clinical practice. T-20 in combination with HAART efficiently inhibits HIV-1 replication, however T-20 resistance has been reported and the number of confirmed resistant-associated mutations is growing.